ITGB3BP is a potential biomarker associated with poor prognosis of glioma

• DOI: 10.1111/jcmm.17127
• Publication Date: 2021-12-25T07:00:02Z
• Authors: Zhendong Liu; Binfeng Liu; Lu Bian; Hongbo Wang; Yulong Jia; Yubo Wang; Wang Zhang; Yanbiao Wang; Zhibin Han; Xingbo Cheng; Xiaoyu Lian; Zhishuai Ren; Yanzheng Gao
• Keywords: 0301 basic medicine; 03 medical and health sciences; Brain Neoplasms; Biomarkers, Tumor; Humans; Nuclear Proteins; Original Articles; Glioma; Signal Transduction; Up-Regulation; 3. Good health

AbstractDespite the growing recognition of ITGB3BP as an essential feature of various cancers, the relationship between ITGB3BP and glioma remains unclear. The main aim of this study was to determine the prognostic and diagnostic value of ITGB3BP in glioma. RNA‐Seq and microarray data from 2222 glioma patients were included, and we found that the expression level of ITGB3BP in glioma tissues was significantly higher than that in normal brain tissues. Moreover, ITGB3BP can be considered an independent risk factor for poor prognosis and has great predictive value for the prognosis of glioma. Gene Set Enrichment Analysis results showed that ITGB3BP contributes to the poor prognosis of glioma by activating tumour‐related signalling pathways. Some small‐molecule drugs were identified, such as hexestrol, which may specifically inhibit ITGB3BP and be useful in the treatment of glioma. The TIMER database analysis results revealed a correlation between the expression of ITGB3BP and the infiltration of various immune cells in glioma. Our findings provide the first evidence that the up‐regulation of ITGB3BP correlates with poor prognosis in human glioma. Thus, ITGB3BP is a potential new biomarker that can be used for the clinical diagnosis and treatment of glioma.